Profiel
Ronald L.
Shazer worked as a Director of Clinical Research Oncology at Bristol Myers Squibb Co. from 2011 to 2013, Director of Clinical Research at Exelixis, Inc. from 2007 to 2009, Head of Clinical Development at Arena Pharmaceuticals, Inc. from 2010 to 2011, Senior Director of Clinical Lead Oncology at Pfizer Inc. from 2015 to 2016, Chief Medical Officer at TRACON Pharmaceuticals, Inc. from 2015 to 2016, and Chief Medical Officer & Senior Vice President at Rebus Holdings, Inc. from 2016 to 2018.
He received his undergraduate degree from the University of California San Diego, his doctorate from New York Medical College, and his MBA from UCLA Anderson School of Management.
Eerdere bekende functies van Ronald Shazer
| Bedrijven | Functie | Einde |
|---|---|---|
| REBUS HOLDINGS, INC. | Hoofd Techniek/Wetenschap/O&O | 12-02-2018 |
| TRACON PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 05-08-2016 |
| PFIZER, INC. | Corporate Officer/Principal | 01-08-2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-08-2013 |
| ARENA PHARMACEUTICALS | Corporate Officer/Principal | 01-08-2011 |
Opleiding van Ronald Shazer
| University of California San Diego | Undergraduate Degree |
| New York Medical College | Doctorate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 5 |
|---|---|
| TRACON PHARMACEUTICALS, INC. | Health Technology |
| REBUS HOLDINGS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| EXELIXIS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
